Q2 EPS Forecast for Viking Therapeutics Reduced by Analyst

Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) - Research analysts at B. Riley dropped their Q2 2025 earnings per share estimates for shares of Viking Therapeutics in a research note issued on Thursday, April 24th. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will post earnings of ($0.43) per share for the quarter, down from their previous estimate of ($0.33). B. Riley has a "Buy" rating and a $96.00 price target on the stock. The consensus estimate for Viking Therapeutics' current full-year earnings is ($1.56) per share. B. Riley also issued estimates for Viking Therapeutics' Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($1.76) EPS, FY2026 earnings at ($2.41) EPS, FY2027 earnings at ($3.48) EPS and FY2028 earnings at ($2.92) EPS.

Several other brokerages have also recently commented on VKTX. Citigroup initiated coverage on shares of Viking Therapeutics in a research report on Friday, February 7th. They issued a "neutral" rating and a $38.00 price target on the stock. Truist Financial reissued a "buy" rating and set a $75.00 target price (down from $95.00) on shares of Viking Therapeutics in a research note on Monday. Piper Sandler decreased their price target on shares of Viking Therapeutics from $74.00 to $71.00 and set an "overweight" rating on the stock in a research report on Thursday, February 6th. HC Wainwright reiterated a "buy" rating and set a $102.00 price objective on shares of Viking Therapeutics in a research report on Thursday, April 24th. Finally, The Goldman Sachs Group initiated coverage on Viking Therapeutics in a report on Tuesday, April 8th. They issued a "neutral" rating and a $30.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $87.15.

Viking Therapeutics Trading Up 3.3 %

VKTX stock traded up $0.93 during trading on Monday, hitting $28.87. The company had a trading volume of 5,222,441 shares, compared to its average volume of 4,537,645. The business has a 50 day moving average of $26.27 and a 200 day moving average of $39.98. The firm has a market capitalization of $3.24 billion, a price-to-earnings ratio of -28.87 and a beta of 0.84. Viking Therapeutics has a fifty-two week low of $18.92 and a fifty-two week high of $81.86.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The biotechnology company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.10). During the same period last year, the business earned ($0.26) EPS. The company's revenue for the quarter was up .0% on a year-over-year basis.

Insider Transactions at Viking Therapeutics

In related news, Director Sarah Kathryn Rouan acquired 1,240 shares of the business's stock in a transaction that occurred on Monday, March 31st. The shares were acquired at an average cost of $24.15 per share, with a total value of $29,946.00. Following the purchase, the director now owns 1,240 shares of the company's stock, valued at approximately $29,946. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.10% of the stock is currently owned by company insiders.

Institutional Trading of Viking Therapeutics

Large investors have recently modified their holdings of the company. Norges Bank bought a new stake in Viking Therapeutics during the 4th quarter valued at approximately $51,464,000. Massachusetts Financial Services Co. MA grew its stake in shares of Viking Therapeutics by 446.7% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,357,241 shares of the biotechnology company's stock worth $54,615,000 after acquiring an additional 1,108,972 shares during the last quarter. Ameriprise Financial Inc. increased its position in Viking Therapeutics by 228.5% during the fourth quarter. Ameriprise Financial Inc. now owns 1,479,596 shares of the biotechnology company's stock worth $59,540,000 after acquiring an additional 1,029,125 shares during the period. Raymond James Financial Inc. acquired a new position in Viking Therapeutics during the 4th quarter valued at $24,888,000. Finally, Man Group plc grew its position in Viking Therapeutics by 3,373.4% in the 4th quarter. Man Group plc now owns 448,732 shares of the biotechnology company's stock worth $18,057,000 after purchasing an additional 435,813 shares during the last quarter. 76.03% of the stock is owned by institutional investors.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.